Certara Inc Ordinary Shares CERT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CERT is a good fit for your portfolio.
News
-
Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform
-
Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
-
Thinking about buying stock in Certara, Stronghold Digital Mining, Society Pass, AgriFORCE Growing Systems, or Luxurban Hotels?
-
Certara Reports Fourth Quarter 2023 Financial Results
-
Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference
-
Certara stock drops after biotech software company misses profit target
Trading Information
- Previous Close Price
- $16.73
- Day Range
- $16.32–16.74
- 52-Week Range
- $11.81–24.70
- Bid/Ask
- $16.18 / $17.00
- Market Cap
- $2.64 Bil
- Volume/Avg
- 421,449 / 538,849
Key Statistics
- Price/Earnings (Normalized)
- 124.91
- Price/Sales
- 7.25
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
- Sector
- Healthcare
- Industry
- Health Information Services
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,391
- Website
- https://www.certara.com
Comparables
Valuation
|
Metric
|
CERT
|
NORDH
|
SPOK
|
|---|---|---|---|
Price/Earnings (Normalized) | 124.91 | — | 20.29 |
Price/Book Value | 2.47 | 2.49 | 1.88 |
Price/Sales | 7.25 | 5.57 | 2.25 |
Price/Cash Flow | 29.36 | 6,605.50 | 9.93 |
Price/Earnings
CERT
NORDH
SPOK
Financial Strength
|
Metric
|
CERT
|
NORDH
|
SPOK
|
|---|---|---|---|
Quick Ratio | 2.52 | 3.05 | 1.15 |
Current Ratio | 2.62 | 3.14 | 1.33 |
Interest Coverage | −1.41 | −1,368.75 | — |
Quick Ratio
CERT
NORDH
SPOK
Profitability
|
Metric
|
CERT
|
NORDH
|
SPOK
|
|---|---|---|---|
Return on Assets (Normalized) | 4.42% | −11.20% | 8.22% |
Return on Equity (Normalized) | 6.44% | −12.74% | 11.46% |
Return on Invested Capital (Normalized) | 6.33% | −11.92% | 10.17% |
Return on Assets
CERT
NORDH
SPOK
Health Information Services Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
GEHC
| GE HealthCare Technologies Inc Common Stock | — | Nrcqdvz | $39.4 Bil | |
VEEV
| Veeva Systems Inc Class A | Krlcvpjpt | Kkt | $32.1 Bil | |
SOLV
| Solventum Corp | — | Tnnryht | $11.0 Bil | |
MTHRF
| M3 Inc | — | Msrhtg | $8.3 Bil | |
MTHRY
| M3 Inc ADR | — | Bwwdnp | $8.2 Bil | |
PMCUF
| Pro Medicus Ltd | — | Chlpxy | $7.2 Bil | |
HQY
| HealthEquity Inc | — | Lmhymc | $6.9 Bil | |
RCM
| R1 RCM Inc | — | Gpb | $5.0 Bil | |
DOCS
| Doximity Inc Class A | — | Ytrskw | $4.6 Bil | |
EVH
| Evolent Health Inc Class A | — | Nvqpn | $3.4 Bil |